HghStudy Information Site Home | Definitions | Bookmark | Site Map


About HGH

Human Growth Hormone
What is Human Growth Hormone
HGH Hormone
History of HGH

Benefits

HGH Anti Aging
HGH Benefits

Products

HGH Products
HGH Injections
Genotropin
Humatrope
Norditropin
Nutropin
Omnitrope
Saizen
Serostim
Ultimate HGH

Oral Spray hGH
FTC Stops False Claims


Side Effects

Side Effects of HGH
Prescription HGH

HGH Treatment

HGH Therapy

Endocrinology

What is Endocrinology?
Endocrine System
Endocrine Diseases

Miscellaneous

Myths & Facts About HGH
HGH Publications
Licit Uses of HGH
Illicit Uses of HGH
Illicit Distribution of HGH

Copyright &
Disclaimer Info
© HGHStudy.com
2004/2008

HGH Growth Hormone

hGH...Human Growth hormone or HGH or hGH

August 1st, 1996, the FDA approved Humatrope (injectable) SOMATROPIN, BIOSYNTHETIC 5MG/VIAL for the use in treatment of adult onset or childhood onset adult HGH deficiency. Now HGH can be prescribed for hormonal deficient adults.

In 1990, the New England Journal of Medicine released an article by D Rudman, AG Feller, HS Nagraj, GA Gergans, PY Lalitha, AF Goldberg, RA Schlenker, L Cohn, IW Rudman, and DE Mattson about "Effects of human growth hormone in men over 60 years old".

It said:
Abstract:
The declining activity of the growth hormone insulin-like growth factor I (IGF-I) axis with advancing age may contribute to the decrease in lean body mass and the increase in mass of adipose tissue that occur with aging.
Methods:
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six month base line period and a six month treatment period that followed. During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic HGH per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment. Plasma IGF-I levels were measured monthly. At the end of each period we measured lean body mass, the mass of adipose tissue, skin thickness (epidermis plus dermis), and bone density at nine skeletal sites.
Results:
In group 1, the mean plasma IGF-I level rose into the youthful range of 500 to 1500 U per liter during treatment, whereas in group 2 it remained below 350 U per liter. The administration of HGH for six months in group 1 was accompanied by an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose-tissue mass, and a 1.6 percent increase in average lumbar vertebral bone density (P<0.05 in each instance). Skin thickness increased 7.1 percent (P=0.07). There was no significant change in the bone density of the radius or proximal femur. In group 2 there was no significant change in lean body mass, the mass of adipose tissue, skin thickness, or bone density during treatment.
Conclusions:
Diminished secretion of HGH is responsible in part for the decrease of lean body mass, the expansion of adipose-tissue mass, and the thinning of the skin that occur in old age. (N Engl J Med 1990; 323:1-6.)

More Info

Human Growth Foundation
Pituitary Society
Pituitary Network Association
Important:
Health Alert


Partners

Heartburn
Acne Medication
Hair Removal

Sponsors

HGHStudy Supporters
Home | Definitions | Bookmark | Site Map
© HGHStudy.com
2004/2008
All information on HGHStudy is for educational purposes only.
For specific medical advice, diagnoses, and treatment, consult your doctor.